Performance effects of imitative entry

Strategic Management Journal

Volumn 29, Issue 8, 2008, Pages 797-817

  Ethiraj, Sendil K ^a   Zhu, David H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Entry timing; Imitation; Product differentiation

Indexed keywords

CHEMOTHERAPY; DIFFERENTIATION (CALCULUS); DRUG DELIVERY; DRUG DOSAGE;

DRUG INDUSTRIES; PRODUCT CATEGORIES; PRODUCT DIFFERENTIATION; RESEARCH QUESTIONS; TRANSITION (JEL CLASSIFICATIONS:E52 ,E41 ,E31); VERTICAL DIFFERENTIATION;

COMPETITION;

EID: 47749092731     PISSN: 01432095     EISSN: 10970266     Source Type: Journal    
DOI: 10.1002/smj.696     Document Type: Article

References (48)

1. Abernathy WJ, Utterback J. 1978. Patterns of industrial innovation. Technology Review 80(7): 40-47.
2. Banerjee PK, Myers SD, Baker A, Andersen M, Bichet S. 2001. High performance drug discovery. Accenture Executive Briefing: Philadelphia, PA.
3. Barney JB. 1986. Strategic factor markets: expectations, luck, and business strategy. Management Science 32(10): 1231-1241.
4. Baron RM, Kenny DA. 1986. The moderator mediator variable distinction in social psychological-research: conceptual, strategic, and statistical considerations. Journal of Personality and Social Psychology 51(6): 1173-1182.
5. Berndt ER, Bui L, Reiley DR, Urban GL. 1995. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 85(2): 100-105.
6. Bohlman JD, Golder PN, Mitra D. 2002. Deconstructing the pioneer's advantage: examining vintage effects and consumer valuations of quality. Management Science 48(9): 1175-1195.
7. CDER. 2006. From test tube to patient: Protecting America's health through human drugs. Center for Drug Evaluation and Research, Food and Drug Administration: Washington, D.C.
8. Chatterjee S, Hadi AS, Price B. 2000. Regression Analysis by Example (3rd edn). John Wiley & Sons: New York.
9. Cohen FJ. 2006. Entry order as a consideration for innovation strategies. Nature Reviews Drug Discovery 5: 285-294.
10. Cohen WM, Levinthal DA. 1990. Absorptive capacity: a new perspective on learning and innovation. Administrative Science Quarterly 35(1): 128-152.
11. Cohen WM, Nelson RR, Walsh JP. 2000. Protecting their intellectual assets: appropriability conditions and why U.S. manufacturing firms patent (or not). Working Paper, National Bureau of Economic Research. NBER: Cambridge, MA.
12. Cyert RM, March JG. 1963. A Behavioral Theory of the Firm. Prentice-Hall: Englewood Cliffs, NJ.
13. Dasgupta P. 1988. Patents, priority and imitation or, the economics of races and waiting games. Economic Journal 98(389): 66-80.
14. Dierickx I, Cool K. 1989. Asset stock accumulation and sustainability of competitive advantage. Management Science 35(12): 1504-1512.
15. DiMasi JA. 1995. Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics 58: 1-14.
16. DiMasi JA. 2001a. New drug development in the United States from 1963 to 1999. Clinical Pharmacology and Therapeutics 69: 286-296.
17. DiMasi JA. 2001b. Risks in new drug development: approval success rates for investigational drugs. Clinical Pharmacology and Therapeutics 69: 297-307.
18. Eaton BC, Lipsey RG. 1998. Product differentiation. In Handbook of Industrial Organization Vol. 1 (5th edn), Schmalensee R, Willig R (eds). Elsevier Science: North Holland, The Netherlands; 723-768.
19. Ethiraj SK, Kale P, Krishnan MS, Singh JV. 2005. Where do capabilities come from and how do they matter? a study in the software services industry. Strategic Management Journal 26(1): 25-45.
20. Ethiraj SK, Levinthal DA, Roy RR. 2008. The dual role of modularity: innovation and imitation. Management Science forthcoming.
21. Golder PN, Tellis GJ. 1993. Pioneer advantage: marketing logic or marketing legend. Journal of Marketing Research 30(2): 158-170.
22. Greve HR. 2000. Market niche entry decisions: competition, learning, and strategy in tokyo banking, 1894-1936. Academy of Management Journal 43(5): 816-836.
23. Huff LC, Robinson WT. 1994. The impact of leadtime and years of competitive rivalry on pioneer market share advantages. Management Science 40(10): 1370-1177.
24. Klepper S. 1996. Entry, exit, growth, and innovation over the product life cycle. American Economic Review 86(3): 562-583.
25. Klepper S. 2002. Firm survival and the evolution of oligopoly. RAND Journal of Economics 33(1): 37-61.
26. Lee H, Smith KG, Grimm CM, Schomburg A. 2000. Timing, order and durability of new product advantages with imitation. Strategic Management Journal 21(1): 23-30.
27. Lieberman MB, Asaba S. 2006. Why do firms imitate each other? Academy of Management Review 31(2): 366-385.
28. Lieberman MB, Montgomery DB. 1988. First-mover advantages. Strategic Management Journal, Summer Special Issue 9: 41-58.
29. Lieberman MB, Montgomery DB. 1998. First-mover (dis)advantages: retrospective and link with the resource-based view. Strategic Management Journal 19(12): 1111-1125.
30. Lu JZ, Comanor WS. 1998. Strategic pricing of new pharmaceuticals. Review of Economics & Statistics 80(1): 108-118.
31. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. 2002. A comparison of methods to test mediation and other intervening variable effects. Psychological Methods 7(1): 83-104.
32. Mansfield E, Schwartz M, Wagner S. 1981. Imitation costs and patents: an empirical study. Economic Journal 91(364): 907-918.
33. Mathieu MP. 2001. Parexel's Pharmaceutical R&D Statistical Sourcebook. Parexel International Corporation: Waltham, MA.
34. Nelson RR. 1991. Why do firms differ, and how does it matter? Strategic Management Journal, Winter Special Issue 12: 61-74.
35. Pepall L. 1997. Imitative competition and product innovation in a duopoly model. Economica 64(254): 265-279.
36. Polidora F. 2006. Institutions and innovations: a longitudinal study of institutional endorsement and firm innovation in the pharmaceutical industry, 1980-2004. PhD diss. Strategy Dept., Ross School of Business. University of Michigan: Ann Arbor.
37. Reed R, DeFillippi RJ. 1990. Causal ambiguity, barriers to imitation, and sustainable competitive advantage. Academy of Management Review 15(1): 88-102.
38. Rivkin J. 2000. Imitation of complex strategies. Management Science 46(6): 824-844.
39. Robinson WT, Fornell C. 1985. Sources of market pioneer advantages in consumer goods industries. Journal of Marketing Research 22(3): 305-317.
40. Rumelt RP. 1984. Toward a strategic theory of the firm. In Competitive Strategic Management, Lamb RB (Ed). Prentice-Hall: Englewood Cliffs: NJ; 556-570.
41. Rumelt RP, Schendel DE, Teece DJ. 1994. Fundamental issues in strategy. In Fundamental Issues in Strategy: A Research Agenda, Rumelt RP, Schendel DE, Teece DJ (eds). Harvard Business School Press: Boston, MA; 9-47.
42. Schmalensee R. 1982. Product differentiation advantages of pioneering brands. American Economic Review 72: 349-365.
43. Teece DJ. 1986. Profiting from technological innovation: implications for integration, collaboration, licensing and public policy. Research Policy 15(6): 285-305.
44. Theil H. 1967. Economics and Information Theory. Rand-McNally: Chicago.
45. Tushman ML, Anderson P. 1986. Technological discontinuities and organizational environments. Administrative Science Quarterly 31(3): 439-465.
46. Urban GL, Carter T, Gaskin S, Mucha Z. 1986. Market share rewards to pioneering brands: an empirical analysis and strategic implications. Management Science 32(6): 645-659.
47. VanderWerf PA, Mahon JF. 1997. Meta-analysis of the impact of research methods on findings of first-mover advantage. Management Science 43(11): 1510-1519.
48. Yeoh PL, Roth K. 1999. An empirical analysis of sustained advantage in the US pharmaceutical industry: impact of firm resources and capabilities. Strategic Management Journal 20(7): 637-653.